Key points are not available for this paper at this time.
Current recommendations for prostate-specific antigen testing are reviewed, as well as the initial results of two randomized trials. The potential risks of screening, including morbidity from overdiagnosis and overtreatment, are described.
Richard M. Hoffman (Wed,) studied this question.